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Aim: We acquired age-matched and sex-matched Sprague-Dawley
rats from 2 independent breeding establishments. Serendipitously,
we observed that constitutive, and bacterial toxin–induced,
expression of major histocompatibility complex (MHC) class II
RT1B chain in the uveal tract was much lower in one of the
cohorts. Activated microglia are known to upregulate MHC II
RT1B expression during optic nerve (ON) degeneration induced by
raised intraocular pressure (IOP). We investigated whether, in a
model of experimental glaucoma, microglial upregulation of MHC
II RT1B was less eﬃcacious and ON degeneration correspondingly
less severe in the cohort of rats with low MHC II RT1B expression.
Methods: Experimental glaucoma was induced by lasering the tra-
becular meshwork using a standard protocol. After 2 weeks of ele-
vated IOP, retinal ganglion cells (RGC) survival, ON degeneration,
and microglial responses were determined in both cohorts of rats.
Results: Raised IOP-induced expression of MHC II RT1B by
microglia was muted in the “Low” cohort compared with the
“High” cohort. Axonal degeneration, RGC loss, and microgliosis
were all signiﬁcantly lower in the cohort of rats with low basal and
induced expression of MHC II RT1B, despite both cohorts dis-
playing IOP responses that were indistinguishable in terms of peak
IOP and IOP exposure.
Conclusions: Expression of MHC II RT1B by activated microglia in
the ON during experimental glaucoma was associated with more
severe RGC degeneration. Further studies are needed to elucidate
the role of MHC II during experimental glaucoma.
Key Words: microglia, major histocompatibility complex, optic
nerve, neurodegeneration
(J Glaucoma 2016;25:681–691)
There is increasing recognition that glial cells in general,and microglia in particular, play important roles in the
survival or death of retinal ganglion cells (RGCs) during
glaucoma.1–4 Microglia serve as the resident immune cells of
the CNS, constantly surveying the environment and
responding rapidly to disruption of local tissue homeostasis.
Neuronal damage triggers microglia to adopt a reactive
phenotype that encompasses multiple changes including
proliferation, migration, phagocytosis of dying neurons,
stimulation of neuroinﬂammatory pathways, and antigen
presentation.3,5 It has indisputably been proven that
microglia within the retina and optic nerve (ON) become
reactive in response to RGC degeneration in animal models
of glaucoma.3,6,7 Of arguably greater interest, however, is
the recent ﬁnding that alterations in microglial function
may, in fact, precede RGC injury in glaucoma.8,9 This result
further focuses debate on whether microglial activation is
detrimental or beneﬁcial to RGC survival. In support of the
hypothesis that reactive microglia are harmful to vulnerable
RGCs is the body of evidence demonstrating that sup-
pression of microglial activity is neuroprotective to RGCs in
models of experimental glaucoma.10–14
The principal route by which microglia induce an
immune response is through expression of major histo-
compatibility complex (MHC) class II.15 Microglial MHC
II is immunohistochemically undetectable in healthy neu-
ronal tissue, but expression is upregulated in response to
neurodegenerative signals. Interestingly, an association has
been uncovered between MHC II genes and CNS neuro-
degeneration. Strain-dependent diﬀerences in susceptibility
to experimental allergic encephalomyelitis (EAE),16 ventral
root avulsion,17 and axonal injury–induced neuropathic
pain18 have all been linked to diﬀerential expression of the
RT1B chain of MHC II. Furthermore, mouse MHC II
knockout models demonstrate reduced axonal injury in
EAE19 and globoid cell leukodystrophy,20 and minimal
dopaminergic neuron loss in a model of Parkinson dis-
ease.21 The combined data suggest that MHC II expression
triggers a greater vulnerability to CNS injury.
While conducting a study investigating proin-
ﬂammatory events in the eye, we acquired age-matched and
sex-matched Sprague-Dawley rats from 2 independent
breeding establishments. In a serendipitous ﬁnding, we
observed that constitutive, and bacterial toxin–induced,
expression of MHC II RT1B in the uveal tract was much
lower in one of the cohorts. We have previously shown that
activated microglia upregulate expression of MHC II RT1B
during axonal degeneration induced by ocular hyper-
tension.22 As an increasing body of evidence supports the
theory that activated microglia contribute to disease pro-
gression during glaucoma, and as MHC II RT1B expres-
sion is both a signature event in reactive microgliosis and is
associated with neuronal injury elsewhere within the nerv-
ous system, we hypothesized that microglial upregulation of
MHC II RT1B would be less eﬃcacious and ON
Received for publication March 30, 2015; accepted April 28, 2016.
From the *Ophthalmic Research Laboratories, South Australian
Institute of Ophthalmology, Hanson Institute Centre for Neuro-
logical Diseases; wDepartment of Ophthalmology and Visual Sci-
ences, University of Adelaide, Adelaide, SA, Australia; and
zDepartment of Ophthalmology, Bern University Hospital and
University of Bern, Inselspital, Bern, Switzerland.
Supported by the NHMRC (project grant: APP1050982) and the
Ophthalmic Research Institute of Ophthalmology.
Disclosure: The authors declare no conﬂict of interest.
Reprints: Glyn Chidlow, DPhil, Ophthalmic Research Laboratories,
South Australian Institute of Ophthalmology, Hanson Institute
Centre for Neurological Diseases, Frome Rd, Adelaide, SA 5000,
Australia (e-mail: glyn.chidlow@health.sa.gov.au).
Copyright r 2016 Wolters Kluwer Health, Inc. All rights reserved.
DOI: 10.1097/IJG.0000000000000447
ORIGINAL STUDY
J Glaucoma  Volume 25, Number 8, August 2016 www.glaucomajournal.com | 681
Copyright r 2016 Wolters Kluwer Health, Inc. All rights reserved.
degeneration during experimental glaucoma would be cor-
respondingly less severe in the colony of rats with low
MHC II RT1B expression. The present study tested this
hypothesis.
METHODS
Experimental Plan
There were 3 phases to the overall study:
(1) Basal expression of MHC II RT1B: We obtained 2
cohorts of age-matched, female rats. These were as
follows: Sprague-Dawley rats (Animal Resources
Centre, Perth; n=7) and Sprague-Dawley rats (Ade-
laide University, Adelaide; n=7). Basal expression of
MHC class II invariant chain (CD74) and MHC II
RT1B chain (Ia antigen; OX-6) within the uveal tract
was assessed in each cohort of rats.
(2) Induced expression of MHC II RT1B: In phase 2,
expression of MHC class II invariant chain and MHC
II RT1B chain within the uveal tract was assessed in
both cohorts of rats at 24 hours following intravitreal
injection of the proinﬂammatory endotoxin lipopoly-
saccharide (LPS) (n=5).
Results of phases 1 and 2 demonstrated that expression
of MHC II RT1B was substantially lower in Sprague-
Dawley rats from Animal Resources Centre, Perth as
compared with Sprague-Dawley rats from Adelaide
University, Adelaide. As a consequence, we proceeded
to phase 3 in which we tested the hypothesis that ON
degeneration during experimental glaucoma would be
less severe in the colony of Sprague-Dawley rats with
low MHC II RT1B expression than in the colony of
Sprague-Dawley rats with phenotypically higher
expression.
(3) Experimental glaucoma: Adult, female Sprague-Dawley
rats (n=28) from the colony with higher MHC II
RT1B (Adelaide University, Adelaide) were designated
cohort “High.” Age-matched and sex-matched rats
(n=28) from the colony with lower expression of
MHC II RT1B (Animal Resources Centre, Perth) were
designated cohort “Low.” Ocular hypertension was
then induced in the right eye of all animals. To
characterize intraocular pressure (IOP) proﬁles for each
rat, peak IOP, IOP integral (area under the curve of the
lasered eye), and the IOP exposure (area under the
curve of the lasered eye minus area under the curve of
control eye) were calculated. After 14 days, ONs and
retinas were analyzed for severity of RGC injury and
for expression of microglial markers.
Animals and Procedures
This study was approved by the SA Pathology/CHN
Animal Ethics committee and conforms with the Australian
Code of Practice for the Care and Use of Animals for
Scientiﬁc Purposes, 2004. All procedures were performed
under appropriate anesthesia and care was taken to mini-
mize suﬀering. All experiments also conformed to the
ARVO Statement for the Use of Animals in Ophthalmic
and Vision Research. Adult Sprague-Dawley rats (220 to
300 g) were housed in a temperature-controlled and
humidity-controlled environment with a 12-hour light, 12-
hour dark cycle, and were provided with food and water ad
libitum.
Endotoxin-induced Uveitis
Rats were anesthetized with isoﬂurane during which
time an intravitreal injection of 0.2% LPS (5 mL in sterile
saline) was performed in 1 eye. The contralateral eye was
untreated. All rats were killed after 24 hours.
Experimental Glaucoma
Rats were anesthetized with 100mg/kg ketamine and
10mg/kg xylazine and local anesthetic drops were applied
to the eye. Ocular hypertension was then induced in the
right eye of each animal by laser photocoagulation of the
trabecular meshwork using a slightly modiﬁed protocol22 of
the method described by Levkovitch-Verbin et al.23 A sec-
ond laser treatment was given on day 7 if the diﬀerence in
IOP between the 2 eyes was <8mm Hg. After brief anes-
thesia with isoﬂurane, IOPs were measured in both eyes at
baseline, day 1, 3, 7, 10, and 14 using a rebound tonometer,
factory calibrated for use in rats. One rat from each cohort
failed to demonstrate an adequate IOP elevation (minimum
increase in IOP of 10mm Hg) and these rats were excluded
from the study. In addition, 2 rats from the High cohort
and 1 rat from the Low cohort were excluded due to
hyphema, whereas 1 rat each from the High and Low
cohorts died under anesthesia. As a result, the High and
Low cohorts comprised n=24 and n=25 rats that con-
tributed to the ﬁnal analysis.
Tissue Processing and Immunohistochemistry
All rats were killed by transcardial perfusion with
physiological saline under deep anesthesia. Both eyes, both
ONs and the optic chiasm were carefully dissected. From
the dissected tissue, a short piece of ON, 1.5mm behind the
globe, was removed for resin processing and subsequently
toluidine blue staining as previously reported.22 Tissues
taken for immunohistochemistry were ﬁxed in 10% buf-
fered formalin for at least 24 hours and then processed for
routine paraﬃn-embedded sections. Globes were embedded
sagitally and chiasmata longitudinally. In all cases, 4-mm
serial sections were cut using a rotary microtome.
Colorimetric immunohistochemistry was performed as
previously described.24,25 Brieﬂy, tissue sections were
deparaﬃnized and endogenous peroxidase activity was
blocked with H2O2. Antigen retrieval was performed by
microwaving sections in 10mM citrate (pH 6.0) and non-
speciﬁc labeling blocked with PBS containing 3% normal
horse serum (PBS-NHS). Sections were incubated over-
night at room temperature in primary antibody (in PBS-
NHS), followed by consecutive incubations with bio-
tinylated secondary antibody (Vector, Burlingame, CA)
and streptavidin-peroxidase conjugate (Pierce, Rockford,
IL). Color development was achieved using 30-,30-dia-
minobenzidine for 5 minutes. Sections were counterstained
with hematoxylin, dehydrated, cleared in histolene, and
mounted. Conﬁrmation of the speciﬁcity of antibody
labeling was judged by the morphology and distribution of
the labeled cells, by the absence of signal when the primary
antibody was replaced by isotype/serum controls, and by
comparison with the expected staining pattern based on our
own, and other, previously published results. All of the
antibodies used in the current study have previously been
validated for use in the retina.
The following primary antibodies were used in the
study: mouse anti-NeuN (1:1500, clone A60; Merck Milli-
pore), rabbit anti-ionized calcium-binding adapter molecule-1
(iba1, 1:20,000, Cat# 019-19741; Wako), mouse anti-CD68
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(1:500, clone ED1; AbDSerotec), mouse anti-MHC II RT1B
chain (1:400, OX-6; AbDSerotec), and goat anti-CD74
(1:1000, Cat# sc-5438; Santa-Cruz).
Evaluation of Immunohistochemistry
Immunolabeling for each antigen was performed in a
single batch and all analyses were conducted in a blinded
manner. Evaluations were by 2 independent observers.
Uveal Tract (Phases 1 and 2 of the Study)
Immunohistochemistry for CD74 and OX-6 was per-
formed using sections of the whole globe. For each animal,
1 photomicrograph was taken from the iris, the ciliary
body, and the choroid using the 20 microscope objective.
The number of positively labeled cells in each photo-
micrograph was determined. Measurements from the 3
uveal areas of each animal were averaged and treated as an
independent data point.
RGC Survival (Phase 3 of the Study)
Two sections from each animal were stained and
quantiﬁed for NeuN. To minimize sampling errors, all
analyses were performed on sections taken at the level of
the ONH. RGCs, immunostained for NeuN, were counted
across the entire retina from ciliary body to ciliary body.
RGC loss was calculated by comparing the glaucomatous
right eye of each animal to the normotensive left eye. NeuN
has been shown to be a robust marker of RGCs and has
been used in numerous studies evaluating RGC survival.
The potential drawback with NeuN is that it also labels
displaced amacrine cells; however, amacrine cells have been
shown not to die in rodent models of glaucoma, thus, any
decrease in NeuN number represents RGC loss.
ON (Phase 3 of the Study)
For each antigen, immunohistochemistry was per-
formed using 1 section of mid ON and 1 section of distal
ON adjacent to the optic decussation as previously descri-
bed.26 One photomicrograph from each location covering
the entire width of the nerve was taken using the 20
microscope objective. Measurements from 1 animal were
averaged and treated as an independent data point. In total,
approximately 6% of the ON was sampled for quantiﬁca-
tion. For iba1, ED1, and CD74, evaluations were per-
formed using the ImageJ 1.42q software package platform
(http://rsb.info.nih.gov/ij/). For counterstained sections,
color deconvolution was applied to extract the DAB
staining. After thresholding, the area of staining was
measured. Left ONs served as controls. For OX-6, the
number of positive cells per micrographic ﬁeld was counted
manually by a single observer.
Evaluation of Semithin Toluidine Blue–stained
ON Cross-Sections
Axon counting was determined using a semi-
quantitative, automated, ﬁxed pattern sampling approach
as previously described.27 All evaluations were performed
in a blinded manner. Five photomicrographs were taken
from each ON cross-section, representing a total sampling
area of approximately 6%. Images were contrast enhanced,
and each axon with a single, intact myelin sheath was
counted using a macroroutine written for ImageJ. The
mean count from the 5 photomicrographs was used to
extrapolate the number of axons in the cross-section.
Axonal loss was calculated by comparing the glaucomatous
right ON of each animal to the normotensive left ON.
Statistical Analysis
IOP data are expressed as mean±SD to reveal the
variability or scatter within the dataset. This allows
FIGURE 1. Expression of MHC class II invariant chain (CD74) and MHC II RT1B chain (Ia antigen; OX-6) within the uveal tract of 2
discrete cohorts of age-matched, female rats. A–D, Example photomicrographs of CD74-positive (A, B) and OX-6-positive (C, D) cells in
the choroid of both cohorts. The cohorts were designated High and Low with regard to their basal expression of OX-6. Scale bar: 25 mm.
E, Quantification of CD74 and OX-6 expression within the uveal tract in the High and Low cohorts. Values are expressed as mean± SEM,
where n=7. ***P<0.001 by Mann-Whitney test (OX-6 data are not normally distributed). Example photomicrographs of CD74-positive
(A, arrow; B, arrow) and OX-6-positive (C, arrow; D) cells in the choroid of both cohorts. MHC indicates major histocompatibility
complex; ONL, outer nuclear layer; PS, photoreceptor segments; RPE, retinal pigment epithelium.
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inferences to be drawn about the reproducibility of the laser
photocoagulation procedure to elevate IOP. All other data
are expressed as mean±SEM, as SEM quantiﬁes the pre-
cision of the mean. For statistical testing, an unpaired t test
was used if parametric assumptions were met (axon loss,
NeuN, iba1); a Mann-Whitney test was used otherwise
(ED1, CD74, OX-6). Statistical analyses, including corre-
lations, were performed by GraphPad Prism 5.0b (Graph-
Pad Software Inc., La Jolla, CA).
RESULTS
Differential Expression of MHC II RT1B Chain
in 2 Cohorts of Sprague-Dawley Rats
We acquired age-matched, female Sprague-Dawley
rats from 2 independent breeding establishments. In a
serendipitous ﬁnding, we anecdotally observed that
expression of MHC II RT1B (Ia antigen; OX-6) was much
lower in the uveal tract in rats from one of the establish-
ments than in the other. To verify this observation, and
further to ascertain whether the lower expression of OX-6
was simply reﬂective of reduced MHC II expression per se
rather than speciﬁcally of the RT1B chain, we quantiﬁed
OX-6 and CD74 immunoreactivities in the uveal tract (iris,
ciliary body, and choroid) of rats from both cohorts
(Figs. 1A–E). Note that CD74 recognizes the invariant
chain of MHC class II. The data showed that both cohorts
of rats featured a similar number of CD74-positive cells
within the uveal tract (P=0.62), but that the number of
OX-6-positive cells was markedly higher in one of the
cohorts (P<0.001; Fig. 1E). The cohorts were thus des-
ignated High and Low with regard to their basal expres-
sion of OX-6.
Next, we investigated expression of MHC II within the
context of a local inﬂammatory environment. Intraocular
administration of the endotoxin LPS induces a nonspeciﬁc
ocular inﬂammation (uveitis) of short duration, which is
characterized by an acute inﬁltration of leukocytes, protein
accumulation in the anterior chamber, anterior and poste-
rior segment inﬂammatory changes, and increased expres-
sion of MHC II.28 In both cohorts of rats, LPS caused
ostensibly similar responses typiﬁed by anterior and pos-
terior inﬂammatory changes and increased expression of
iba1 (data not shown) and CD74 (Fig. 2A, B) throughout
the uveal tract. However, expression of OX-6 was markedly
lower in the Low cohort as compared with the High cohort
(P<0.01; Figs. 2C–E).
IOP Characteristics in the High and Low Cohorts
During Experimental Glaucoma
There was no diﬀerence in peak IOP (P=0.41), IOP
integral (P=0.94), or IOP exposure (P=0.36) between the
Low and High cohorts over the 2-week period of exper-
imental glaucoma (Table 1). IOP values reported are similar
to those previously documented by other groups using the
same model.29,30
FIGURE 2. Expression of iba1, MHC class II invariant chain (CD74), and MHC II RT1B chain (OX-6) within the High and Low cohorts at 1
day after intravitreal injection of the proinflammatory endotoxin lipopolysaccharide. A, Example photomicrographs of CD74-positive (A,
B) and OX-6-positive (C, D) cells in the choroid of both cohorts. Lipopolysaccharide-treated rats from both cohorts showed increased
numbers of CD74 cells within the choroid. In the High cohort, numerous OX-6-positive cells are visible within the choroid after
lipopolysaccharide treatment. In contrast, OX-6-positive cells are scarce in the Low cohort (arrow). Scale bar: 25 mm. E, Quantification of
CD74 and OX-6 expression within the uveal tract in the High and Low cohorts. Values are expressed as mean±SEM, where n=5.
**P<0.01 by Mann-Whitney test (OX-6 data are not normally distributed). LPS indicates lipopolysaccharide; RPE, retinal pigment
epithelium.
TABLE 1. IOP Responses in the High and Low Cohorts During
Experimental Glaucoma
Cohort Peak IOP IOP Exposure IOP Integral
High (n=24) 39.1±5.8 167.2±74.5 349.7±76.1
Low (n=25) 40.6±7.3 191.8±107.9 351.7±108.3
P 0.41 0.36 0.94
Peak IOP is mm Hg±SD. IOP exposure is total positive integral data in
units of mm Hg (mean±SD). IOP integrals are also in units of mm Hg
(mean±SD).
P-values are given for the comparison between the High and the Low
experimental cohorts (Student unpaired t test, 2-tailed).
IOP indicates intraocular pressure.
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FIGURE 3. Retinal ganglion cell (RGC) survival at 2 weeks after induction of experimental glaucoma in the High and Low cohorts. A–C,
Example photomicrographs of transverse sections of retinas immunolabeled for NeuN, featuring overview of posterior eyecup (control
eye from High cohort) with position of optic nerve head indicated (A, arrow), control retina from High cohort (B), and injured retina
from High cohort (C). Scale bar: A = 500mm; B, C=50mm. D, Estimated loss of NeuN-positive RGCs (untreated left eye minus glau-
comatous right eye) in transverse section of retina taken through the optic nerve head. Values are expressed as mean±SEM, where
n=24-25. *P<0.05 by Student unpaired t test. GCL indicates ganglion cell layer; INL, inner nuclear layer; ONH, optic nerve head.
FIGURE 4. Axonal integrity at 2 weeks after induction of experimental glaucoma in the High and Low cohorts. A–D, Example pho-
tomicrographs of toluidine blue–stained cross-sections of control optic nerves from the Low (A) and High (B) cohorts, injured optic nerve
from the Low cohort (C), and injured optic nerve from the High cohort (D). Scale bar: 10 mm. E, Estimated axon loss (untreated left optic
nerve minus glaucomatous right optic nerve) in the Low and High cohorts. Values are expressed as mean± SEM, where n=24-25.
**P<0.01 by Student unpaired t test.
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RGC Loss in the High and Low Cohorts During
Experimental Glaucoma
Loss of RGCs was assessed by quantiﬁcation of
NeuN-positive cells in the ganglion cell layer across the
entire retina (Figs. 3A–C). NeuN has repeatedly been
demonstrated to represent a reliable marker for determin-
ing RGC survival in models of RGC degeneration. The
mean loss of NeuN-positive cells (glaucomatous eye minus
control eye) was 109.4±13.2 in the High cohort versus
61.8±13.7 in the Low cohort (Fig. 3D). This diﬀerence
was statistically signiﬁcant (P=0.02).
Axon Loss in the High and Low Cohorts During
Experimental Glaucoma
Estimated axon loss was assessed in semithin, toluidine
blue–stained transverse sections of the proximal (intra-
orbital) ON (Figs. 4A–D) using a ﬁxed pattern sampling
approach. The mean loss of axons (glaucomatous ON
minus control ON) was 26,413±3534 in the High cohort
versus 11,596±3229 in the Low cohort (Fig. 4E). This
diﬀerence was statistically signiﬁcant (P<0.01).
Microglial Responses in the High and Low
Cohorts During Experimental Glaucoma
Microglial number and phagocytic activity in the ON,
as detected by labeling for iba1 and ED1, respectively, have
been shown to correlate positively with the extent of axonal
injury during experimental glaucoma.22 To verify that ON
damage in the High cohort was, on average, greater than
that in the Low cohort, we immunolabeled longitudinal
segments of the intracranial ON with iba1 and ED1
(Figs. 5A–F). Both markers were signiﬁcantly (P<0.001
for iba1; P<0.01 for ED1) more abundant in the High
cohort compared with the Low cohort (Figs. 5G, H), the
extent to which reﬂected the amount of axonal damage in
each cohort.
MHC II Responses in the High and Low Cohorts
During Experimental Glaucoma
Minimal expression of CD74 (MHC II invariant
chain) was detectable in uninjured ONs of both the High
and Low cohorts (Figs. 6A, B). At 2 weeks after induction
of experimental glaucoma, however, there was a marked
increase in the number of CD74-positive cells in the ONs of
both cohorts (Figs. 6C, D). Double labeling showed that
FIGURE 5. Analysis of microglial activation at 2 weeks after induction of experimental glaucoma in the High and Low cohorts. A–F,
Representative images of Iba1 and ED1 (arrows) expression in control (cont) optic nerves, and injured optic nerves of the High and Low
cohorts. Scale bar: 50mm. G and H, Quantification of iba1 and ED1 expression in longitudinal segments of the intracranial optic nerve.
Values are expressed as mean± SEM. ***P<0.001 by Student unpaired t test (iba1 data are normally distributed); **P<0.01 by Mann-
Whitney test (ED1 data are not normally distributed). ON indicates optic nerve.
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CD74 expression occurred exclusively in iba1-positive
microglia (data not shown). Quantiﬁcation of the relative
responses showed that CD74 was signiﬁcantly (P<0.001)
more abundant in the High cohort compared with the Low
cohort (Fig. 6E). We were interested in delineating the
extent to which the CD74 response reﬂected the severity of
axonal injury; thus, we performed correlations of the esti-
mated axon count with the abundance of CD74 immu-
noreactivity for each animal (Figs. 6F, G). Analysis of the
data revealed a highly signiﬁcant correlation between the 2
parameters in both cohorts (P=0.001 for the High and
Low cohorts). As for iba1 and ED1, expression of CD74 by
microglia was proportional to the severity of axonal
damage.
Analogous to CD74, there was negligible expression of
OX-6 (MHC class II RT1B) in control ON tissue (Figs. 7A,
D). At 2 weeks after induction of experimental glaucoma,
there was an increase in the number of OX-6-positive cells
in the ONs of the High cohort (Figs. 7B, C, G). As for iba1,
ED1, and CD74, the extent of OX-6 expression in the High
cohort was typically related to the severity of injury
(Figs. 7B, C). Indeed, there was an excellent correlation
between the CD74 and OX-6 immunoreactivities (r=0.75;
P<0.001) in this cohort (Fig. 8A). In contrast, the
majority of animals in the Low cohort failed to display a
commensurate induction of OX-6 immunoreactivity at 2
weeks after induction of experimental glaucoma with
staining absent or weak in virtually all animals (Figs. 7E,
F). Quantiﬁcation of the relative responses showed that
OX-6 was dramatically more abundant in the High cohort
compared with the Low cohort (Fig. 7G). Scrutiny of the
relative abundances of CD74 and OX-6 in the Low cohort
revealed minimal expression of OX-6 in animals with mild
or moderate damage with somewhat greater expression in
the more severely injured ONs (Fig. 8B).
DISCUSSION
In the current study, we compared RGC survival, ON
degeneration, and microglial responses following chronic
FIGURE 6. Analysis of expression of MHC II invariant chain (CD74) by microglia at 2 weeks after induction of experimental glaucoma in
the High and Low cohorts. A–D, Representative images of CD74-positive microglia in control (A, B) and injured (C, D) ONs of the High
and Low cohorts. Scale bar: 50mm. E, Quantification of CD74 expression in longitudinal segments of the intracranial ON. Values are
expressed as mean± SEM. ***P<0.001 by Mann-Whitney test (CD74 data are not normally distributed). F and G, Correlation between
estimated axon counts (in transverse sections of the proximal ON) and abundance of CD74 immunoreactivity (in longitudinal sections
of the intracranial ON) at 2 weeks after induction of experimental glaucoma in the High (E) and Low (F) cohorts. Each data point
represents 1 animal. MHC indicates major histocompatibility complex; ON, optic nerve.
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FIGURE 7. Analysis of expression of MHC II RT1B chain (OX-6) by microglia at 2 weeks after induction of experimental glaucoma in the
High and Low cohorts. A–F, Representative images of OX-6-positive microglia (arrows) in control (cont) ONs (A, D), moderately injured
(B, E), and robustly injured (C, F) ONs of the High and Low cohorts. Scale bar: 50 mm. G, Quantification of OX-6 expression in
longitudinal segments of the intracranial ON. Values are expressed as mean±SEM. ***P<0.001 by Mann-Whitney test (OX-6 data are
not normally distributed). MHC indicates major histocompatibility complex; ON, optic nerve.
FIGURE 8. Correlation between CD74 and OX-6 immunoreactivities in longitudinal sections of the intracranial ON at 2 weeks after
induction of experimental glaucoma in the High (A) and Low (B) cohorts. Each data point represents 1 animal. ON indicates optic nerve.
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elevation of IOP in 2 discrete cohorts of Sprague-Dawley
rats with diﬀering constitutive expression of MHC II
RT1B. The results showed that in the cohort of rats with
innately higher expression of MHC II RT1B, elevated IOP-
induced axonal degeneration and RGC loss were sig-
niﬁcantly greater than in the cohort of rats with low basal
expression of MHC II RT1B, despite both cohorts dis-
playing IOP responses that were indistinguishable in terms
of peak IOP and IOP integral. Iba1 and ED1, respectively,
markers of total microglial number and phagocytosis, were
elevated in the damaged ONs of both cohorts, with the
extent of expression in each cohort reﬂecting the severity of
axonal injury. Microglial expression of both the invariant
chain of MHC II and the RT1B chain was very low in the
uninjured ONs of each cohort. In the injured ONs of both
cohorts, microglia upregulated expression of the invariant
chain of MHC II, the extent to which correlated with the
severity of axonal injury. A diﬀerential response, however,
was apparent with regard to MHC II RT1B: in the cohort
of rats with very low basal expression of MHC II RT1B,
microglia within damaged ONs largely failed to upregulate
expression of MHC II RT1B, yet, in the cohort of rats with
a higher basal level of MHC II RT1B, microglia within
injured ONs did upregulate expression of MHC II RT1B.
Thus, it can be concluded that microglial expression of
MHC II RT1B was associated with more severe axonal
degeneration during experimental glaucoma.
The most important point to make when discussing the
present results is that the data cannot, and should not, be
viewed as providing direct evidence for a causative relationship
between expression of MHC II RT1B by microglia and RGC
degeneration. The deﬁnitive ﬁnding of greater RGC vulner-
ability to chronic IOP elevation in the cohort of rats that
displayed markedly higher basal and induced expression of
MHC II RT1B may simply be coincidental. Multiple genetic
diﬀerences (polymorphisms resulting in allelic variation) could
exist between the 2 cohorts of rats, any one of which might
have played a causative role in the observed results. As an
outbred stock, the Sprague-Dawley necessarily comprises
populations of rats with innate genetic variation. Limited
inbreeding will inevitably occur within each isolated pop-
ulation, which, when combined with environmental factors,
also speciﬁc to each facility, will, over time, lead to further
genetic drift within the individual populations of rats.
Although this scenario likely accounts for the observed dif-
ference in basal and induced MHC II RT1B expression
between the 2 cohorts—and it should be noted that MHC II
RT1B expression following neuronal injury is particularly
strain dependent31—it will also encompass an unknown
number of other genes that could be involved in degeneration.
Although the data presented herein do not provide
direct evidence of cause-eﬀect, they do serve to focus
attention on the need for research that investigates the
relationship between reactive microglia and RGC injury in
general, and microglial MHC II expression and RGC
degeneration in particular. Our previous results,22 and
those of others,8,13,32–34 have clearly established that axonal
injury subsequent to chronically elevated IOP is associated
with a spatially and temporally coordinated reactive
microgliosis, the extent of which reﬂects the severity of
injury. The microglial response is characterized by pro-
liferation, expression of markers indicative of phagocytosis,
and induction of immunologic cell surface markers,
including MHC II. The present results correspond with the
expected proﬁle: in both cohorts of rats, axonal injury was
associated with an increased number of microglia, an
increased presence of ED1 (a marker of phagocytosis), and
induction of CD74 (a marker of MHC II).
A fundamental question that has repeatedly been posed
in recent years is whether microglial activation is detrimental
or beneﬁcial to RGC survival.6 Although this issue remains
unresolved, an increasing body of evidence lends support to
the former scenario rather than the latter. Most pertinently,
suppression of microglial activity, for example by admin-
istration of minocycline, has been shown to be neuroprotective
to RGCs in models of experimental glaucoma.10–14 Moreover,
inhibition of reactive microgliosis also augments RGC survival
in other injury models, such as ON transection/crush,10,35,36
NMDA-induced excitotoxicity,37 and ischemia-reperfusion.38
The precise method by which minocycline protects RGCs,
and, by implication, the speciﬁc mechanism(s) by which the
microglia are toxic to RGCs, remain unclear, but suggested
pathways of microglial toxicity include release of proin-
ﬂammatory mediators and activation of the immune sys-
tem.3,6,7 In this context, it is noteworthy that minocycline has
been shown to downregulate MHC II RT1B expression within
spinal cord microglia and macrophages and concurrently
reduce the severity of EAE symptoms.39
MHC II molecules expressed by activated microglia
present antigenic fragments to the immune system for recog-
nition and activation of CD4+ T cells. In autoimmune dis-
eases of the CNS, such as EAE and multiple sclerosis, MHC II
expression by activated microglia is central to the disease
pathogenesis through reactivation of myelin autoreactive T
cells.19,40,41 Although glaucoma is not a classic autoimmune
disease, there is some credence to the idea that autoimmunity
plays a role.42 Interestingly, however, MHC II is also impli-
cated in the pathology of neurodegenerative conditions that
are not of a primary inﬂammatory nature. Thus, loss of
dopaminergic neurons in models of Parkinson disease is
completely prevented in MHC class II knockout mice as
compared with wild-type mice.21 MHC class II knockout mice
likewise show reduced CNS pathology in a model of globoid
cell leukodystrophy.20 Furthermore, strain-dependent diﬀer-
ences in susceptibility to various CNS conditions have been
linked to diﬀerential expression of the RT1B chain of MHC II.
For example, in ventral root avulsion,17 a standardized
mechanical nerve trauma model, the ACI and PVG.1AV1 rat
strains display low expression of MHC II RT1B by microglia
and high survival of lesioned motorneurons, whereas the DA
strain has high MHC II RT1B expression and low survival of
lesioned motorneurons.31,43,44
In conclusion, the present results indicate the possibility
of an association between MHC II expression and RGC
degeneration in experimental glaucoma. MHC II expression
after nerve injury is known to be subject to complex genetic
regulation,45 but the genetic proﬁles of the Sprague-Dawley
cohorts in the current study remain unknown. Therefore,
more targeted studies are needed to investigate the role of
MHC II in experimental glaucoma. Speciﬁc experiments of
interest would include comparison of RGC degeneration
following induction of experimental glaucoma in rat strains
with diﬀerent MHC II haplotypes. Of even greater relevance
would be analysis of severity of glaucomatous pathology in
MHC II knockout versus wild-type mice.
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